Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
IC1-H82E8 | Human | Biotinylated Human ICAM-1 / CD54 Protein, His,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
![]() ![]() |
IC1-M82E8 | Mouse | Biotinylated Mouse ICAM-1 / CD54 Protein, His,Avitag™ (MALS verified) | ![]() |
![]() ![]() |
|
IC1-H52H5 | Human | Human ICAM-1 / CD54 Protein, His Tag | ![]() |
![]() ![]() |
|
IC1-H5250 | Human | Human ICAM-1 / CD54 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
Immobilized Human ITGALB2, His tag at 5 μg/mL (100 μL/well) can bind Human ICAM-1, Fc Tag (Cat. No. IC1-H5250) with a linear range of 0.082-1.28 μg/mL (Routinely tested).
The purity of Biotinylated Human ICAM-1, His,Avitag (Cat. No. IC1-H82E8) is more than 85% and the molecular weight of this protein is around 65-80kDa verified by SEC-MALS.
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Tocopherol acetate | DSE-9912 | Approved | Ephynal, Aquasol E | Venous Thromboembolism; Atherosclerosis; Intermittent Claudication; Thrombosis; Diabetic Retinopathy | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Coxsackievirus A21 (Viralytics) | V-937; CVA-21 | Phase 2 Clinical | Viralytics | Head and Neck Neoplasms; Urinary Bladder Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Melanoma; Neoplasm Metastasis | Details |
AIC-100 | AIC-100 | Phase 1 Clinical | Affyimmune Therapeutics | Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms | Details |
Bersanlimab | BI-505 | Phase 2 Clinical | Bioinvent International | Smoldering Multiple Myeloma; Multiple Myeloma | Details |
This web search service is supported by Google Inc.